Douglas Ward
Chief Executive Officer chez LUMOS DIAGNOSTICS HOLDINGS LIMITED
Fortune : 18 905 $ au 31/03/2024
Profil
Douglas Ward is currently the Chief Executive Officer, Director, and Managing Director at Lumos Diagnostics Holdings Ltd.
He previously served as the Chief Executive Officer at Personal Genome Diagnostics, Inc. from 2016 to 2020.
Additionally, he held the position of Vice President of Strategy and Business Development at Hologic, Inc. Mr. Ward completed his undergraduate degree at Ohio Wesleyan University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/10/2023 | 475 000 ( 0,10% ) | 18 905 $ | 31/03/2024 |
Postes actifs de Douglas Ward
| Sociétés | Poste | Début |
|---|---|---|
| LUMOS DIAGNOSTICS HOLDINGS LIMITED | Chief Executive Officer | 21/06/2022 |
Anciens postes connus de Douglas Ward
| Sociétés | Poste | Fin |
|---|---|---|
Personal Genome Diagnostics, Inc.
 Personal Genome Diagnostics, Inc. BiotechnologyHealth Technology Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD. | Chief Executive Officer | 21/04/2020 |
| HOLOGIC, INC. | Corporate Officer/Principal | - |
Formation de Douglas Ward
| Ohio Wesleyan University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| HOLOGIC, INC. | Health Technology |
| LUMOS DIAGNOSTICS HOLDINGS LIMITED | Health Technology |
| Entreprise privées | 1 |
|---|---|
Personal Genome Diagnostics, Inc.
Personal Genome Diagnostics, Inc. BiotechnologyHealth Technology Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD. | Health Technology |
